$150M
Series C funding amount
Health tech startup Forus has raised $150 million in a Series C funding round led by Bain Capital Ventures, bringing its total valuation to $3 billion.
08 Sep
Every figure reported in pharmaceuticals news this week, with what each figure measures, when it was reported and where it was published.
68 figures were reported across 40 pharmaceuticals articles in this window. The table lists the 60 carried by the highest-ranked articles.
Health tech startup Forus has raised $150 million in a Series C funding round led by Bain Capital Ventures, bringing its total valuation to $3 billion.
08 Sep
Health tech startup Forus has raised $150 million in a Series C funding round led by Bain Capital Ventures, bringing its total valuation to $3 billion.
08 Sep
Health tech startup Forus has raised $150 million in a Series C funding round led by Bain Capital Ventures, bringing its total valuation to $3 billion.
08 Sep
Novartis shareholders are expressing concern over the company's M&A strategy following the failure of the muscle-wasting drug del-desiran in a late-stage trial.
11 Sep
Novartis shareholders are expressing concern over the company's M&A strategy following the failure of the muscle-wasting drug del-desiran in a late-stage trial.
11 Sep
Novartis shareholders are expressing concern over the company's M&A strategy following the failure of the muscle-wasting drug del-desiran in a late-stage trial.
11 Sep
Novartis shareholders are expressing concern over the company's M&A strategy following the failure of the muscle-wasting drug del-desiran in a late-stage trial.
11 Sep
Moderna and Merck & Co. announced that their mRNA cancer vaccine successfully extended patient survival in a phase 3 clinical study.
11 Sep
The hacking group ShinyHunters leaked data belonging to 6.4 million individuals following a cyberattack on the medical supplier McKesson.
10 Sep
The hacking group ShinyHunters leaked data belonging to 6.4 million individuals following a cyberattack on the medical supplier McKesson.
10 Sep
A Fifth Circuit panel heard arguments on September 9, 2026, regarding Louisiana's attempt to block the FDA's 2023 decision to remove in-person dispensing requirements for mifepristone.
09 Sep
On September 7, 2026, the U.S. Department of Health and Human Services (HHS) announced four permanent senior leadership appointments at the FDA.
07 Sep (reported 09 Sep)
Novartis announced that its neuromuscular drug candidate delpacibart etedesiran failed the Phase III HARBOR trial for myotonic dystrophy type 1 (DM1) after missing the primary endpoint of vHOT improvement.
09 Sep
Novartis announced that its neuromuscular drug candidate delpacibart etedesiran failed the Phase III HARBOR trial for myotonic dystrophy type 1 (DM1) after missing the primary endpoint of vHOT improvement.
09 Sep
Novartis announced that its neuromuscular drug candidate delpacibart etedesiran failed the Phase III HARBOR trial for myotonic dystrophy type 1 (DM1) after missing the primary endpoint of vHOT improvement.
09 Sep
The National Commission into the Regulation of AI in Healthcare has published its recommendations for a future regulatory framework for AI in the UK healthcare sector.
09 Sep — due 10 Sep 2026
The National Commission into the Regulation of AI in Healthcare has published its recommendations for a future regulatory framework for AI in the UK healthcare sector.
09 Sep — due 10 Sep 2026
Google's Mandiant threat intelligence team reported that extortion groups are increasingly targeting proprietary AI data, including models and research, for ransom.
08 Sep
Novartis announced that the phase 3 Harbor trial for its drug candidate del-desiran failed to meet its primary endpoint.
08 Sep
BrainChild Bio has raised $116 million in Series A financing to fund a pivotal Phase II trial for its lead CAR T-cell therapy candidate, BCB-276.
08 Sep
BrainChild Bio has raised $116 million in Series A financing to fund a pivotal Phase II trial for its lead CAR T-cell therapy candidate, BCB-276.
08 Sep
Interra Health announced on September 10, 2026, that its health tech platform now supports the Medicare GLP-1 Bridge program.
01 Jul (reported 13 Sep)
Interra Health announced on September 10, 2026, that its health tech platform now supports the Medicare GLP-1 Bridge program.
01 Jul (reported 13 Sep)
Interra Health announced on September 10, 2026, that its health tech platform now supports the Medicare GLP-1 Bridge program.
01 Jul (reported 13 Sep)
GE HealthCare is reportedly in advanced talks to acquire the radiopharmaceutical developer Sofie Biosciences.
13 Sep
GSK and Hansoh Pharma reported that their antibody-drug conjugate, risvutatug rezetecan, achieved a median overall survival of 18.5 months in a phase 3 lung cancer trial.
12 Sep
A recent study found that GLP-1 drug prescriptions for children aged 8 to 11 without diabetes increased between 2019 and 2026 in the United States.
05 Sep (reported 12 Sep)
A recent study found that GLP-1 drug prescriptions for children aged 8 to 11 without diabetes increased between 2019 and 2026 in the United States.
05 Sep (reported 12 Sep)
A recent study found that GLP-1 drug prescriptions for children aged 8 to 11 without diabetes increased between 2019 and 2026 in the United States.
05 Sep (reported 12 Sep)
A recent study found that GLP-1 drug prescriptions for children aged 8 to 11 without diabetes increased between 2019 and 2026 in the United States.
05 Sep (reported 12 Sep)
Users of GLP-1 weight loss drugs like Wegovy, Ozempic, and Mounjaro report experiencing social stigma and interpersonal conflict within their families.
12 Sep
Users of GLP-1 weight loss drugs like Wegovy, Ozempic, and Mounjaro report experiencing social stigma and interpersonal conflict within their families.
12 Sep
Researchers from the Wellcome Sanger Institute, University of Cambridge, and University College London published a study in Nature Genetics on September 11, 2026, regarding the impact of cancer treatments on healthy tissue.
11 Sep
Andy Plump, the President of Research and Development at Takeda, will depart from the company in June 2027.
11 Sep
In August 2026, the biopharmaceutical industry saw 12 companies announce workforce reductions affecting 526 employees, representing a 90% decrease compared to August 2025.
10 Sep
In August 2026, the biopharmaceutical industry saw 12 companies announce workforce reductions affecting 526 employees, representing a 90% decrease compared to August 2025.
10 Sep
In August 2026, the biopharmaceutical industry saw 12 companies announce workforce reductions affecting 526 employees, representing a 90% decrease compared to August 2025.
10 Sep
Tyra Biosciences reported initial phase 2 clinical trial data for its drug candidate dabogratinib in treating bladder cancer.
09 Sep
Tyra Biosciences reported initial phase 2 clinical trial data for its drug candidate dabogratinib in treating bladder cancer.
09 Sep
Biochemist Douglas Yao announced on September 8, 2026, that he synthesized a new schizophrenia drug candidate named PAC-3310 in his home garage.
08 Sep (reported 09 Sep)
Biochemist Douglas Yao announced on September 8, 2026, that he synthesized a new schizophrenia drug candidate named PAC-3310 in his home garage.
08 Sep (reported 09 Sep)
Employers Health and Judi Health have partnered to launch StarkRx, a new cost-plus pharmacy benefit management (PBM) model.
09 Sep
Jesse Mendelsohn, Senior Vice President at Model N, discusses the complexities of the 340B Drug Pricing Program in a Pharmaceutical Executive podcast episode.
09 Sep
Solstice Oncology has raised $225 million in a series A funding round.
09 Sep
Schrödinger has launched a new biotechnology company named Tectora Therapeutics, which will focus on immunology and inflammation research.
09 Sep
The US Food and Drug Administration (FDA) announced that priority review voucher fees will decrease for the 2027 fiscal year.
09 Sep
On September 9, 2026, the US FDA granted accelerated approval to AstraZeneca's drug Etcamah.
09 Sep
Kura Oncology has launched a new biotech spinout company to develop a next-generation diabetes therapy.
09 Sep
Encoded Therapeutics, a neuro-focused biotechnology company backed by Google, has secured $275 million in a Series F funding round.
09 Sep
Mexico has introduced a new regulatory reliance pathway for pharmaceutical products that have already been approved by Brazil's health authorities.
08 Sep
BrainChild, a startup spun out of Seattle Children’s Hospital, has raised $116 million in funding.
08 Sep
Spyre Therapeutics has achieved a phase 2 clinical trial success with its anti-IL-23 antibody, marking the third positive result in its three-pronged strategy for treating inflammatory bowel disease.
08 Sep
RNAV8 Bio has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to participate in the PROPEL program, which aims to develop programmable RNA medicines.
08 Sep
RNAV8 Bio has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to participate in the PROPEL program, which aims to develop programmable RNA medicines.
08 Sep
Insilico Medicine published a study in Nature Biotechnology on September 7, 2026, regarding its AI-generated drug, rentosertib.
07 Sep
Insilico Medicine published a study in Nature Biotechnology on September 7, 2026, regarding its AI-generated drug, rentosertib.
07 Sep
Insilico Medicine published a study in Nature Biotechnology on September 7, 2026, regarding its AI-generated drug, rentosertib.
07 Sep
GSK has agreed to pay Hutchmed $110 million upfront for global rights, excluding Greater China, to develop the cancer drug candidate HMPL-A830.
03 Sep (reported 07 Sep)
GSK has agreed to pay Hutchmed $110 million upfront for global rights, excluding Greater China, to develop the cancer drug candidate HMPL-A830.
03 Sep (reported 07 Sep)
BioSpace reports that job postings for life sciences companies in California increased by 31% year-over-year in August 2026.
10 Sep
60 of 68 figures are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
Publishers cited most often across the events on this page.
Choose the topics and sources that matter to you. Dailyn turns them into one concise digest.
Build my digest →Dailyn’s analysis engine screens the week’s reporting for relevance, deduplicates overlapping coverage into distinct dated events, and ranks those events by significance, source corroboration and recency. The highest-ranked events form the core of the weekly briefing.
Every line is a fact taken verbatim from a single dated article, and that article is linked in the same row. Nothing on the page is written or inferred beyond the article set.
The analysis engine extracts facts, entities and figures from the week’s reporting, and the editorial synthesis is generated from that event data. Published claims remain traceable to the underlying reporting.
A new briefing is issued for every ISO week, and the key-numbers section is refreshed with it. Each page states the exact window of dates it covers.
Dailyn’s analysis engine processes everything its monitored sources published this week: it deduplicates overlapping coverage, clusters reporting into distinct dated events, extracts the companies, deals and figures involved, and ranks the results by significance, corroboration and recency.
Everything Dailyn’s monitored sources published across the seven-day window.
The engine filters out off-topic and low-quality reporting.
Articles the engine tagged with this industry inside the window.
Sector articles that reported at least one figure inside the window.
The figures this page prints, each quoted exactly as its article reported it.
Events ranked by significance, corroboration and recency.
Every line on this page is a fact taken verbatim from a single dated article, with that article linked in the same row. Nothing on this page is written or inferred beyond the article set.
Duplicate reports of the same event are collapsed to one entry; the corroborating-source count says how many outlets carried it.
Dates are publication dates. Where an article states a different date for the event itself, that date is shown first and the publication date in brackets. A date the article gives for something still to come is shown as "due".
A figure is listed exactly as the article reported it. Figures are not converted, rebased, summed or compared across articles.
Every event stays linked to the reporting it was built from.
Pick the topics and sources that matter to you. Dailyn reads them every day and sends one concise digest.